Channels
Drug Development, News, Syndication, Xconomy »
San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs |  |
|
Posted by sandiegobiotech April 8th, 2013 .
| |
| No Comments |
San Diego-based Ambrx says it’s getting an upfront payment of $15 million under a deal with Japan’s Astellas to help develop an undisclosed number of targets for antibody drug conjugates in cancer….
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Still Waiting for the Ships to Come in at Third Rock Ventures | |
|
Posted by sandiegobiotech March 28th, 2013 .
| |
| No Comments |
Third Rock Ventures was in the enviable position of turning away some institutional investors when the life sciences venture firm recently closed on $516 million for its third venture fund. So first…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
New Domain Partnership Focuses on China’s Emerging Healthcare Market | |
|
Posted by sandiegobiotech March 13th, 2013 .
| |
| No Comments |
Domain Associates, the life sciences venture firm based in San Diego and Princeton, NJ, says today it has formed a partnership with the Beijing-based firm Elite Consulting to license biomedical…
[[Click headline to continue reading.]]
More...Diagnostics, News, Syndication, Xconomy »
Japan’s Ajinomoto Acquires Contract Drug Maker Althea Technologies | |
|
Posted by sandiegobiotech March 6th, 2013 .
| |
| No Comments |
[Updated 3/7/13 7:34 am to include terms, other details. See below.] Ajinomoto, a Japanese food, pharmaceuticals, and specialty chemicals manufacturer, is acquiring San Diego-based Althea…
[[Click headline to continue reading.]]
More...Diagnostics, News, Syndication, Xconomy »
Natera Joins Quest in Four-Way Battle for Prenatal Genetic Tests | |
|
Posted by sandiegobiotech February 20th, 2013 .
| |
| No Comments |
[Corrected: 9:10 am PT] Parents have long wanted to know whether they are about to bring a child into the world with a chromosomal abnormality like Down syndrome. There’s never been a noninvasive,…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Sophiris Bio Files $75M IPO, Plans Pivotal Trials of Prostate Drug | |
|
Posted by sandiegobiotech February 19th, 2013 .
| |
| No Comments |
San Diego-based Sophiris Bio, which was founded in Vancouver B.C. and already trades on the Toronto Stock Exchange, intends to list its shares on the Nasdaq and raise almost $75 million through an…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
Elcelyx Closes on $20M to Advance Appetite-Control Compounds | |
|
Posted by sandiegobiotech February 14th, 2013 .
| |
| No Comments |
It’s Valentine’s Day, and San Diego’s Elcelyx Therapeutics is feeling the love. The startup, focused on obesity and diabetes, says today it has closed on $20 million in Series C financing led by the…
[[Click headline to continue reading.]]
Diagnostics, News, Syndication, Xconomy »
J&J Creates Space at Janssen Labs for Life Sciences Entrepreneurs | |
|
Posted by sandiegobiotech February 5th, 2013 .
| |
| No Comments |
Johnson & Johnson’s innovation center, Janssen Labs, has admitted 18 early stage companies since opening its “no strings attached” business accelerator program in San Diego a year ago. Now the…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
California Stem Cell Agency Shifts Focus to Clinical Treatments | |
|
Posted by sandiegobiotech January 31st, 2013 .
| |
| No Comments |
California’s stem cell research funding agency has been shifting gears, and California entrepreneurs stand to benefit. The California Institute for Regenerative Medicine (CIRM) plans to spend…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
FDA OKs First-in-Class Drug From Isis for Rare Cholesterol Disorder | |
|
Posted by sandiegobiotech January 29th, 2013 .
| |
| No Comments |
The FDA today approved the cholesterol-lowering drug mipomersen (Kynamro)—the first major RNA therapeutic developed by Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS). Isis has been developing…
[[Click headline to continue reading.]]
